Orchicia Pharmaceutical Industires specializes in ophthalmic treatments and is considered the second largest ophthalmic producer in Egypt among 45 multinational, regional and local companies with a market share of 13.3% in 2012. It is the first and only company in the Middle East and North Africa region to install Blow-Fill Seal technology, and, in 2013, it successfully raised foreign direct investment from an international Private Equity fund. Since then, it has embarked on several expansion plans and intends to establish in 2017 the first Single Dose Unit line in the region. In 2016, Orchidia had 335 employees, 20% of which were females. The company's mission is to provide the best quality of treatment with the most affordable price to reach all patients. Its export capabilities extend to a very wide range of markets including Senegal, Ethiopia, Tanzania, Kenya, Iraq, Qatar, South Sudan, Somalia and Saudi Arabia.